Back
ADMA Biologics faces securities class action after short-seller allegations trigger share slide

ADMA Biologics faces securities class action after short-seller allegations trigger share slide

New Jersey lawsuit covers investors who bought ADMA securities between August 9, 2024 and March 25, 2026, alleging channel stuffing, an undisclosed related-party transaction and inadequate internal controls; lead plaintiff motions are due August 10, 2026.

Fact Check
All three sources independently corroborate every element of the claim: a New Jersey (D.N.J.) securities class action (Mazzarino v. ADMA Biologics); a class period of August 9, 2024 to March 25, 2026; allegations of channel stuffing, an undisclosed related-party transaction, and inadequate internal controls; and an August 10, 2026 lead plaintiff (application) deadline. The BFA Law and Robbins Geller notices also confirm the lawsuit followed a Culper Research short-seller report that triggered the March 2026 share slide, consistent with the claim's framing.
    Reference: 123
Summary

ADMA Biologics, Inc. and certain executives are facing a securities class action in the U.S. District Court for the District of New Jersey after a Culper Research report alleged the company boosted reported 2025 growth through channel stuffing and an undisclosed related-party distributor relationship. The suit, captioned Mazzarino v. ADMA Biologics, Inc., et al., alleges materially false or misleading statements and omissions, including claims involving inadequate internal controls, under federal securities laws. The complaint covers investors who bought ADMA securities between August 9, 2024 and March 25, 2026, and investors have until August 10, 2026 to seek appointment as lead plaintiff. ADMA shares fell from $13.59 on March 23, 2026 to $11.33 on March 24, then to $9.63 on March 25, and later to $8.29 on March 29 after a Cantor downgrade reported by Investing.com.

Terms & Concepts
  • channel stuffing: Shipping or pushing excess product to distributors to inflate reported sales before underlying demand is realized.
  • lead plaintiff: The investor appointed by the court to represent the proposed class in a securities class action.
  • Sections 10(b) and 20(a): U.S. Securities Exchange Act provisions commonly cited for securities fraud and control-person liability claims.